Grant: Engage Grants Program
University of British Columbia
$24,990.00
Thymidylate kinase as a target for therapeutics to counter gram-negative bacterial infection
EF 2013-14
Résumé
Pseudomonas aeruginosa is a significant human pathogen that is naturally drug resistant. P. aeruginosa is anopportunistic pathogen that causes infections notably in burn victims and in the lungs of individuals with cysticfibrosis. Treatment options would benefit from a broader spectrum of antibiotics that could be usedsynergistically. Thymidylate kinase (TMK) produces thymidine diphosphate (dTDP) a key build block of DNA. The essentiality of TMK has led to the investigation of this enzyme as a target for novel therapeutics by IndelTherapeutics. The specific aim of the project is to obtain crystal structures of PaTMK with bound inhibitorsidentified by Indel using their technology platform. We will analyze these crystal structures of PaTMKinhibitor complexes to design more specific inhibitors with favorable pharmaceutical features that will lead totherapeutically viable antibiotics.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
452482-2013
Name nom
Murphy, Michael
Department département
Microbiology and Immunology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
24990
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
Thymidylate kinase as a target for therapeutics to counter gram-negative bacterial infection
Keyword
NSERC
Application summary
Pseudomonas aeruginosa is a significant human pathogen that is naturally drug resistant. P. aeruginosa is anopportunistic pathogen that causes infections notably in burn victims and in the lungs of individuals with cysticfibrosis. Treatment options would benefit from a broader spectrum of antibiotics that could be usedsynergistically. Thymidylate kinase (TMK) produces thymidine diphosphate (dTDP) a key build block of DNA. The essentiality of TMK has led to the investigation of this enzyme as a target for novel therapeutics by IndelTherapeutics. The specific aim of the project is to obtain crystal structures of PaTMK with bound inhibitorsidentified by Indel using their technology platform. We will analyze these crystal structures of PaTMKinhibitor complexes to design more specific inhibitors with favorable pharmaceutical features that will lead totherapeutically viable antibiotics.